Research Article
Smart Immune-evasive AI Nanobot for Systemic Cancer and Viral Eradication with Regenerative Capabilities (3rd Edition)
Gazy Abdalla Ahmed Ebrahim*
Issue:
Volume 14, Issue 1, March 2026
Pages:
1-5
Received:
21 October 2025
Accepted:
24 February 2026
Published:
5 March 2026
Abstract: This conceptual systems-architecture study presents a foresight-driven blueprint for an artificial intelligence (AI)–powered, immune-evasive nanobot designed for systemic cancer and viral eradication with integrated regenerative capabilities. The proposed platform combines biomimetic immune camouflage, an embedded convolutional neural network (CNN)–based diagnostic core, multimodal nanosensors, stimuli-responsive therapeutic release, regenerative payload deployment, and a theoretical autonomous energy module within a modular nanoscale framework. Unlike conventional nanocarriers that rely primarily on passive targeting mechanisms such as the enhanced permeability and retention (EPR) effect, this system is designed to perform real-time pathological sensing, AI-guided target verification, and adaptive therapeutic activation directly within the in vivo environment. The nanobot architecture integrates validated advances in immune-mimetic membrane cloaking, AI-assisted medical diagnostics, smart nanocarriers, and regenerative biology into a unified theoretical platform. A structured Technology Readiness Level (TRL) assessment and comparative systems analysis are provided to evaluate subsystem maturity and identify translational gaps. While significant technological barriers remain—particularly in nanoscale AI hardware fabrication, in vivo energy harvesting, and micro-integration stability—the model offers an interdisciplinary roadmap toward autonomous and regenerative precision nanomedicine. This study does not present experimental validation but instead proposes a strategic conceptual framework intended to guide future research, engineering development, and ethical regulatory discussions surrounding intelligent therapeutic nanodevices.
Abstract: This conceptual systems-architecture study presents a foresight-driven blueprint for an artificial intelligence (AI)–powered, immune-evasive nanobot designed for systemic cancer and viral eradication with integrated regenerative capabilities. The proposed platform combines biomimetic immune camouflage, an embedded convolutional neural network (CNN)...
Show More
Review Article
Pulsed Electromagnetic Fields in Cancer Therapy:
A Review of Experimental and Clinical Evidence
Hung Van Le*
Issue:
Volume 14, Issue 1, March 2026
Pages:
6-16
Received:
18 February 2026
Accepted:
28 February 2026
Published:
10 March 2026
DOI:
10.11648/j.crj.20261401.12
Downloads:
Views:
Abstract: Pulsed electromagnetic fields (PEMF) are emerging as a non-invasive adjunct in cancer therapy. Initially approved for orthopedic applications such as bone healing and tissue regeneration, PEMF has demonstrated broader biological effects including modulation of inflammation, angiogenesis, cellular metabolism, and signal transduction. Increasing experimental and early clinical evidence suggests that specific electromagnetic field exposures may inhibit tumor cell proliferation, induce apoptosis, disrupt mitotic spindle formation, and impair angiogenesis across multiple cancer types. This review synthesizes findings from studies investigating low- and high-intensity PEMF, intermediate-frequency tumor-treating alternating electric fields, and tumor-specific amplitude-modulated radiofrequency electromagnetic fields (AM-RF EMF) in cancer cell lines, animal models, and preliminary human clinical trials. Across these modalities, therapeutic responses appear highly dependent on field strength, frequency, waveform, exposure duration, and tumor biology. While intermediate-frequency alternating electric fields selectively target dividing cells through mitotic disruption, AM-RF EMF protocols have demonstrated early clinical activity in hepatocellular carcinoma and other malignancies without significant toxicity. Low- and higher-intensity PEMF exposures have also shown antiproliferative and pro-apoptotic effects in diverse tumor models, often enhancing sensitivity to chemotherapy, radiation, and targeted therapies. Despite encouraging results, clinical translation remains limited due to mechanistic heterogeneity and the absence of standardized treatment protocols. To address these challenges, this review proposes a framework integrating cancer genomics, structural biology, and thermodynamic modeling to guide rational design of electromagnetic field therapies. By estimating the electromagnetic field strengths required to perturb protein–ligand interactions or disrupt key oncogenic signaling pathways, PEMF protocols may be tailored to individual tumor molecular profiles. Although current biophysical estimates remain preliminary, they provide a conceptual basis for hypothesis-driven optimization. Rigorous randomized clinical trials, mechanistic validation, and standardized exposure parameters will be essential to establish the role of PEMF as a precision, mechanism-informed component of multimodal cancer therapy.
Abstract: Pulsed electromagnetic fields (PEMF) are emerging as a non-invasive adjunct in cancer therapy. Initially approved for orthopedic applications such as bone healing and tissue regeneration, PEMF has demonstrated broader biological effects including modulation of inflammation, angiogenesis, cellular metabolism, and signal transduction. Increasing expe...
Show More
